<?xml version="1.0" ?>
<document id="0b104ed7194e21c4ba47460db675b638b0d29bc4">
  <chunk id="0b104ed7194e21c4ba47460db675b638b0d29bc4.c0" text="Development and validation of an Lc-MS/MS method for detection and quantification of in vivo derived metabolites of [pyr 1 ]apelin-13 in humans">
    <entity charOffset="101-112" id="0b104ed7194e21c4ba47460db675b638b0d29bc4.c0.e0" ontology_id="CHEBI_25212" text="metabolites" type="chemical"/>
  </chunk>
  <chunk id="0b104ed7194e21c4ba47460db675b638b0d29bc4.c1" text="pyr 1 ]apelin-13 is the predominant apelin peptide isoform in the human cardiovascular system and plasma. to date, few studies have investigated [pyr 1 ]apelin-13 metabolism in vivo in rats with no studies examining its stability in humans. We therefore aimed to develop an Lc-MS/MS method for detection and quantification of intact [Pyr 1 ]apelin-13 and have used this method to identify the metabolites generated in vivo in humans. [pyr 1 ]apelin-13 (135 nmol/min) was infused into six healthy human volunteers for 120 minutes and blood collected at time 0 and 120 minutes after infusion. Plasma was extracted in the presence of guanidine hydrochloride and analysed by Lc-MS/MS. Here we report a highly sensitive, robust and reproducible method for quantification of intact [Pyr 1 ]apelin-13 and its metabolites in human plasma. Using this method, we showed that the circulating concentration of intact peptide was 58.3 Â± 10.5 ng/ml after 120 minutes infusion. We demonstrated for the first time that in humans, [pyr 1 ]apelin-13 was cleaved from both termini but the C-terminal was more susceptible to cleavage. Consequently, of the metabolites identified, [Pyr 1 ]apelin-13 (1-12) , [pyr 1 ]apelin-13 (1-10) and [pyr 1 ]apelin-13 (1-6) were the most abundant. these data suggest that apelin peptides designed for use as cardiovascular therapeutics, should include modifications that minimise C-terminal cleavage.">
    <entity charOffset="43-50" id="0b104ed7194e21c4ba47460db675b638b0d29bc4.c1.e0" ontology_id="CHEBI_16670" text="peptide" type="chemical"/>
    <entity charOffset="393-404" id="0b104ed7194e21c4ba47460db675b638b0d29bc4.c1.e1" ontology_id="CHEBI_25212" text="metabolites" type="chemical"/>
    <entity charOffset="631-640" id="0b104ed7194e21c4ba47460db675b638b0d29bc4.c1.e2" ontology_id="CHEBI_30087" text="guanidine" type="chemical"/>
    <entity charOffset="641-654" id="0b104ed7194e21c4ba47460db675b638b0d29bc4.c1.e3" ontology_id="CHEBI_17883" text="hydrochloride" type="chemical"/>
    <entity charOffset="802-813" id="0b104ed7194e21c4ba47460db675b638b0d29bc4.c1.e4" ontology_id="CHEBI_25212" text="metabolites" type="chemical"/>
    <entity charOffset="905-912" id="0b104ed7194e21c4ba47460db675b638b0d29bc4.c1.e5" ontology_id="CHEBI_16670" text="peptide" type="chemical"/>
    <entity charOffset="1136-1147" id="0b104ed7194e21c4ba47460db675b638b0d29bc4.c1.e6" ontology_id="CHEBI_25212" text="metabolites" type="chemical"/>
    <entity charOffset="1295-1303" id="0b104ed7194e21c4ba47460db675b638b0d29bc4.c1.e7" ontology_id="CHEBI_16670" text="peptides" type="chemical"/>
  </chunk>
  <chunk id="0b104ed7194e21c4ba47460db675b638b0d29bc4.c2" text="Apelin is an endogenous ligand of the apelin receptor, initially characterised from bovine stomach extracts as a 77-amino acid preproprotein 1 . The prepro-apelin is further cleaved into shorter but functional fragments including apelin-36, apelin-17, apelin-13 and [Pyr 1 ]apelin-13 that contain an evolutionary conserved 12-amino acid C-terminal 1-3 . [Pyr 1 ]apelin-13 was subsequently identified as the most predominant isoform of the apelin family of peptides in the cardiovascular system 4,5 , and the major circulating form of the peptide 6 . In the cardiovascular system, apelin is the most potent endogenous inotropic agent yet identified 4 . Apelin modulates vascular tone in vivo, decreasing blood pressure when infused into rats and dilating resistance vessels when infused into human forearm 7-9 . In vitro, apelin causes nitric oxide-dependent vasodilation of human splanchnic artery 10 , although a nitric oxide-independent, prostanoid dependent vasodilation in humans has been reported 4 . Apelin acted as a vasoconstrictor in endothelium denuded vessels via a direct action on vascular smooth muscle cells whilst also acting as a potent angiogenic factor and mitogen of endothelial cells 4,11 . Based on these beneficial effects, apelin was proposed as a potential therapeutic target in cardiovascular diseases. For example, apelin administration showed cardioprotective effects in heart failure 12 , and ameliorated the development of pulmonary arterial hypertension in rats 13,14 and humans 15 . In addition, the protective effects of apelin has been">
    <entity charOffset="24-30" id="0b104ed7194e21c4ba47460db675b638b0d29bc4.c2.e0" ontology_id="CHEBI_52214" text="ligand" type="chemical"/>
    <entity charOffset="122-126" id="0b104ed7194e21c4ba47460db675b638b0d29bc4.c2.e1" ontology_id="CHEBI_37527" text="acid" type="chemical"/>
    <entity charOffset="252-261" id="0b104ed7194e21c4ba47460db675b638b0d29bc4.c2.e2" ontology_id="CHEBI_80131" text="apelin-13" type="chemical"/>
    <entity charOffset="274-283" id="0b104ed7194e21c4ba47460db675b638b0d29bc4.c2.e3" ontology_id="CHEBI_80131" text="apelin-13" type="chemical"/>
    <entity charOffset="332-336" id="0b104ed7194e21c4ba47460db675b638b0d29bc4.c2.e4" ontology_id="CHEBI_37527" text="acid" type="chemical"/>
    <entity charOffset="362-371" id="0b104ed7194e21c4ba47460db675b638b0d29bc4.c2.e5" ontology_id="CHEBI_80131" text="apelin-13" type="chemical"/>
    <entity charOffset="456-464" id="0b104ed7194e21c4ba47460db675b638b0d29bc4.c2.e6" ontology_id="CHEBI_16670" text="peptides" type="chemical"/>
    <entity charOffset="538-545" id="0b104ed7194e21c4ba47460db675b638b0d29bc4.c2.e7" ontology_id="CHEBI_16670" text="peptide" type="chemical"/>
    <entity charOffset="940-950" id="0b104ed7194e21c4ba47460db675b638b0d29bc4.c2.e8" ontology_id="CHEBI_26347" text="prostanoid" type="chemical"/>
    <entity charOffset="1084-1090" id="0b104ed7194e21c4ba47460db675b638b0d29bc4.c2.e9" ontology_id="CHEBI_5133" text="action" type="chemical"/>
    <entity charOffset="1176-1183" id="0b104ed7194e21c4ba47460db675b638b0d29bc4.c2.e10" ontology_id="CHEBI_52290" text="mitogen" type="chemical"/>
    <entity charOffset="1472-1484" id="0b104ed7194e21c4ba47460db675b638b0d29bc4.c2.e11" ontology_id="DOID_10763" text="hypertension" type="disease"/>
    <pair e1="0b104ed7194e21c4ba47460db675b638b0d29bc4.c2.e0" e2="0b104ed7194e21c4ba47460db675b638b0d29bc4.c2.e11" id="0b104ed7194e21c4ba47460db675b638b0d29bc4.c2.p0" relation="true"/>
    <pair e1="0b104ed7194e21c4ba47460db675b638b0d29bc4.c2.e1" e2="0b104ed7194e21c4ba47460db675b638b0d29bc4.c2.e11" id="0b104ed7194e21c4ba47460db675b638b0d29bc4.c2.p1" relation="true"/>
    <pair e1="0b104ed7194e21c4ba47460db675b638b0d29bc4.c2.e2" e2="0b104ed7194e21c4ba47460db675b638b0d29bc4.c2.e11" id="0b104ed7194e21c4ba47460db675b638b0d29bc4.c2.p2" relation="true"/>
    <pair e1="0b104ed7194e21c4ba47460db675b638b0d29bc4.c2.e3" e2="0b104ed7194e21c4ba47460db675b638b0d29bc4.c2.e11" id="0b104ed7194e21c4ba47460db675b638b0d29bc4.c2.p3" relation="true"/>
    <pair e1="0b104ed7194e21c4ba47460db675b638b0d29bc4.c2.e4" e2="0b104ed7194e21c4ba47460db675b638b0d29bc4.c2.e11" id="0b104ed7194e21c4ba47460db675b638b0d29bc4.c2.p4" relation="true"/>
    <pair e1="0b104ed7194e21c4ba47460db675b638b0d29bc4.c2.e5" e2="0b104ed7194e21c4ba47460db675b638b0d29bc4.c2.e11" id="0b104ed7194e21c4ba47460db675b638b0d29bc4.c2.p5" relation="true"/>
    <pair e1="0b104ed7194e21c4ba47460db675b638b0d29bc4.c2.e6" e2="0b104ed7194e21c4ba47460db675b638b0d29bc4.c2.e11" id="0b104ed7194e21c4ba47460db675b638b0d29bc4.c2.p6" relation="true"/>
    <pair e1="0b104ed7194e21c4ba47460db675b638b0d29bc4.c2.e7" e2="0b104ed7194e21c4ba47460db675b638b0d29bc4.c2.e11" id="0b104ed7194e21c4ba47460db675b638b0d29bc4.c2.p7" relation="true"/>
    <pair e1="0b104ed7194e21c4ba47460db675b638b0d29bc4.c2.e8" e2="0b104ed7194e21c4ba47460db675b638b0d29bc4.c2.e11" id="0b104ed7194e21c4ba47460db675b638b0d29bc4.c2.p8" relation="true"/>
    <pair e1="0b104ed7194e21c4ba47460db675b638b0d29bc4.c2.e9" e2="0b104ed7194e21c4ba47460db675b638b0d29bc4.c2.e11" id="0b104ed7194e21c4ba47460db675b638b0d29bc4.c2.p9" relation="true"/>
    <pair e1="0b104ed7194e21c4ba47460db675b638b0d29bc4.c2.e10" e2="0b104ed7194e21c4ba47460db675b638b0d29bc4.c2.e11" id="0b104ed7194e21c4ba47460db675b638b0d29bc4.c2.p10" relation="true"/>
  </chunk>
</document>
